High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil by Doi, Yohei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2007, p. 3388–3390 Vol. 51, No. 9
0066-4804/07/$08.000 doi:10.1128/AAC.00443-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
High Prevalence of Metallo--Lactamase and 16S rRNA Methylase
Coproduction among Imipenem-Resistant Pseudomonas aeruginosa
Isolates in Brazil
Yohei Doi,1* Angela C. R. Ghilardi,2 Jennifer Adams,1
Doroti de Oliveira Garcia,2 and David L. Paterson1
Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania,1 and
Instituto Adolfo Lutz, Sa˜o Paulo, Brazil2
Received 30 March 2007/Returned for modification 13 May 2007/Accepted 11 June 2007
Rates of metallo--lactamase and 16S rRNA methylase production were investigated in 51 imipenem-
resistant Pseudomonas aeruginosa clinical isolates collected from hospitals in Sa˜o Paulo, Brazil. Of them, 57%
and 75% produced SPM-1 and RmtD, respectively. Of note, 51% produced both enzymes, suggesting that their
coproduction is already common in this geographic area.
Treatment of infections due to Pseudomonas aeruginosa is
becoming increasingly complicated by its tendency to acquire
resistance to multiple classes of antimicrobials (12). The agents
typically used to treat these infections include antipseudomo-
nal penicillins, cephalosporins, carbapenems, fluoroquinolo-
nes, and aminoglycosides. The production of metallo--lacta-
mases (MBLs) contributes substantially to panresistant phenotypes
in P. aeruginosa because they confer resistance to all classes of
-lactam antimicrobials except aztreonam (10). Various MBLs
including IMP, VIM, SPM, and GIM types have been reported
for P. aeruginosa (12). Of note, SPM-type MBLs have been
found only in Brazil thus far (13).
Methylation of 16S rRNA has emerged as a mechanism of
high-level aminoglycoside resistance among gram-negative
pathogens in recent years (3). Five such methylases, ArmA and
RmtA through RmtD, have been reported to date. The most
recently identified methylase is RmtD, which we reported pre-
viously for a panresistant P. aeruginosa strain isolated near Sa˜o
Paulo, Brazil (4). This enzyme confers high-level resistance to
most aminoglycosides in clinical use. In this particular strain,
the coproduction of RmtD and SPM-1 played a substantial
role in the panresistant phenotype. The present study was
conducted to determine the prevalence of coproduction of
these enzymes among P. aeruginosa clinical isolates in Brazil.
Nonrepetitive imipenem-resistant P. aeruginosa isolates from a
total of 49 patients hospitalized at seven hospitals in the Sa˜o
Paulo area in 2005 and 2006 were collected. One patient had
two isolates with different pulsed-field gel electrophoresis
(PFGE) patterns, and another patient had two isolates with
identical PFGE patterns but markedly different susceptibility
patterns. Thus, 51 imipenem-resistant P. aeruginosa isolates
were included in the study. Sites of the specimens were as
follows: 28 from urine, 8 from blood, 7 secretions from various
sites, 3 from cerebrospinal fluid, 2 from catheter tip, 1 from
bronchoalveolar lavage fluid, 1 from ascitic fluid, and 1 from
nasal swab.
The MICs of imipenem, meropenem, aztreonam, amikacin,
gentamicin, arbekacin, ciprofloxacin, and colistin were ob-
tained using either the standard agar dilution method or Etest
(AB Biodisk, Solna, Sweden) (2). The MICs of imipenem were
32 g/ml or higher for all the isolates, verifying the high degree
of resistance to this agent in this collection. For meropenem,
MICs were 8 g/ml or higher. When the phenotypic test using
sodium mercaptoacetic acid was performed to detect MBL
production (1), 29 of 51 isolates (57%) yielded a positive
result.
PFGE was performed with SpeI (New England Biolabs,
Beverly, MA) as the restriction enzyme for the genomic DNA.
Electrophoresis was performed with the CHEF III DR system
(Bio-Rad, Hercules, CA). The pulses were increased linearly
from 5.3 to 34.9 s for 24 h at 14°C. Seventeen pulsotypes were
observed among the 51 isolates by PFGE. Eight of the pulso-
types comprising 32 isolates from six hospitals were possibly
related to each other (“pulsotype A,” consisting of subtypes A1
through A8), whereas the other nine pulsotypes were unre-
lated (pulsotypes B through J) according to criteria described
previously by Tenover et al. (Table 1 and Fig. 1) (14). Pulso-
type A was thus the most prevalent genotype in hospitals in this
area.
PCR was conducted to detect the MBL gene blaSPM (6) and
the 16S rRNA methylase gene rmtD. PCR for blaIMP-1,
blaIMP-2, and blaVIM-2 was performed for all the blaSPM-nega-
tive isolates (11). For rmtD, the following primers were used to
produce a 401-bp amplicon: rmtD-F (5-CGGCACGCGATT
GGGAAGC-3) and rmtD-R (5-CGGAAACGATGCGACG
AT-3). The thermal cycle conditions included an initial dena-
turation step at 96°C for 5 min followed by 30 cycles at 96°C for
30 s, 55°C for 30 s, and 72°C for 1 min, with a final extension
step at 72°C for 5 min. All the 29 isolates that produced a
positive phenotypic test for MBL production yielded an am-
plicon consistent with blaSPM. When representative amplicons
from different PFGE pulsotypes were sequenced, their de-
duced amino acid sequences matched that of SPM-1 within
the amplicons (15). PCR results for blaIMP-1, blaIMP-2, and
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blaVIM-2 were all negative. These results suggested that SPM-1
is indeed the most predominant MBL among P. aeruginosa
isolates in this geographic area. The median MIC of imipenem
was greater than 256 g/ml for blaSPM-positive isolates and 64
mg/ml for blaSPM-negative isolates (Table 2). For rmtD, 38
isolates (75%) yielded an amplicon. Deduced amino acid se-
quences of representative amplicons from different PFGE pro-
files were identical to that of RmtD within the amplicons. The
MICs of arbekacin, amikacin, and gentamicin for the rmtD-
positive isolates were always greater than 256 g/ml. Of the 29
blaSPM-positive isolates, 26 were positive for rmtD as well.
Thus, the prevalence of coproduction of SPM-1 and RmtD in
this collection of imipenem-resistant P. aeruginosa isolates was
51% (26/51), and that among the SPM-1-producing isolates
reached 90% (26/29). All of the blaSPM-positive isolates be-
longed to pulsotype A. Most of the rmtD-positive strains were
also observed within pulsotype A, whereas some belonged to
pulsotypes E, H, and J. These results suggest that the rmtD and
blaSPM genes are spreading in Sa˜o Paulo hospitals mostly by
means of interhospital transmission of strains belonging to
pulsotype A.
When the MICs of aminoglycosides were stratified accord-
ing to the PCR results for rmtD, the sensitivities of arbekacin,
amikacin, and gentamicin MICs greater than 256 g/ml in
predicting the presence of rmtD were all 100% (Table 3). On
the other hand, the specificities of their MICs equal to or less
than 256 g/ml were 77%, 100%, and 54%, respectively.
Therefore, amikacin was the best single agent to predict ami-
noglycoside resistance mediated by the production of RmtD.
This result is in contrast with a previous finding with a collec-
tion of Acinetobacter sp. strains, where arbekacin displayed
better specificity than amikacin (8). Although arbekacin gen-
erally retains better activity than amikacin in the presence of
an aminoglycoside-modifying enzyme among gram-negative
bacteria, this advantage may be lost when multiple modifying
enzymes with different substrate specificities are produced si-
multaneously in a bacterium (5). Both agents are also known to
FIG. 1. PFGE patterns of the study isolates. The pulsotypes were aligned using Bionumerics software version 4.0 (Applied Maths, Sint-
Martens-Latem, Belgium).
TABLE 1. Characteristics of study isolates
Pulsotype and
subtype
Total no. of
isolates Hospital(s)
No. of isolates (%)
blaSPM
positive
rmtD
positive
A 32 b, c, d, e, f, g 29 (91) 29 (91)
1 12 b, c, e, f, g 11 12
2 10 b, d, g 9 8
3 1 g 1 1
4 3 b 2 3
5 3 b 3 3
6 1 b 1 1
7 1 b 1 1
8 1 b 1 0
B 1 a 0 (0) 0 (0)
C 5 b 0 (0) 0 (0)
D 1 a 0 (0) 0 (0)
E 7 b 0 (0) 7 (100)
F 1 g 0 (0) 0 (0)
G 1 b 0 (0) 0 (0)
H 1 d 0 (0) 1 (100)
I 1 a 0 (0) 0 (0)
J 1 b 0 (0) 1 (100)
TABLE 2. MICs of imipenem, meropenem, aztreonam, amikacin,
ciprofloxacin, and colistin in the presence or absence of blaSPM
blaSPM status
(no. of
isolates)
Antibiotic
No. of isolates with MICs (g/ml) of:
256 256 128 64 32 16 8 4 2 1
Positive (29) Imipenem 21 6 2
Meropenem 17 10 1 1
Aztreonam 5 19 5
Amikacin 26 3
Ciprofloxacin 1 1 8 15 2 1 1
Colistin 12 8 7 2
Negative (22) Imipenem 17 5
Meropenem 2 10 9 1
Aztreonam 1 2 3 4 7 3 2
Amikacin 12 4 1 4 1
Ciprofloxacin 4 3 3 7 1 1 3
Colistin 2 3 11 5 1
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be substrates of efflux pumps in P. aeruginosa (9). A combina-
tion of these resistance mechanisms may thus lead to high
aminoglycoside MICs even in the absence of 16S rRNA meth-
ylase. The MICs of imipenem, meropenem, aztreonam, ami-
kacin, ciprofloxacin, and colistin were then stratified depend-
ing on the PCR results for blaSPM (Table 2). Higher MICs of
the carbapenems and lower MICs of aztreonam were observed
in blaSPM-positive isolates, as expected, reflecting the substrate
specificities of the MBL (10). High-level amikacin resistance
was more frequent in blaSPM-positive isolates due to the fre-
quent coproduction of RmtD. MICs of ciprofloxacin were vari-
able regardless of the presence or absence of blaSPM. Some
isolates with elevated colistin MICs (8 to 16 g/ml) were ob-
served in both groups, which differed from a previous study
that reported 100% susceptibility to this agent for imipenem-
resistant P. aeruginosa isolates in Brazil (6).
In summary, our study demonstrates that the coproduction
of SPM-1 and RmtD is a common phenomenon observed in
half of the imipenem-resistant P. aeruginosa isolates in hospi-
tals in Sa˜o Paulo, Brazil. A recent nationwide surveillance
study from Brazil reported that as many as 37% of P. aerugi-
nosa isolates recovered in Brazilian hospitals were resistant to
imipenem (7). Furthermore, it was also reported that MIC90s
of amikacin, tobramycin, and gentamicin against P. aeruginosa
were all greater than 256 g/ml. Our findings, coupled with
those surveillance data, suggest that high-level aminoglycoside
resistance mediated by the production of 16S rRNA methylase
may already be disseminated in Brazilian hospitals.
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TABLE 3. MICs of aminoglycosides in the presence or
absence of rmtD
rmtD status
(no. of isolates) Aminoglycoside
No. of isolates with MIC (g/ml) of:
256 256 128 64 32 16 8 4
Positive (38) Arbekacin 38
Amikacin 38
Gentamicin 38
Negative (13) Arbekacin 3 2 1 6 1
Amikacin 4 1 7 1
Gentamicin 6 1 3 3
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